Boronic Acids

• 

  Subject Areas on Research

  • "Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial. 
  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma. 
  • A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. 
  • Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. 
  • Boronic acid porphyrin receptor for ginsenoside sensing. 
  • Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. 
  • Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant. 
  • Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. 
  • Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. 
  • Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. 
  • Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. 
  • Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injury. 
  • Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products. 
  • Chemical functionalization of oligodeoxynucleotides with multiple boronic acids for the polyvalent binding of saccharides. 
  • Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury. 
  • Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model. 
  • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. 
  • Function of nuclear factor kappaB in pancreatic cancer metastasis. 
  • Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. 
  • Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. 
  • LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH). 
  • Multiple myeloma, version 1.2013. 
  • Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. 
  • NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. 
  • Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. 
  • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. 
  • Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. 
  • Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. 
  • Phenylboronic Acid-polymers for Biomedical Applications. 
  • Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. 
  • Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis. 
  • Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation. 
  • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections. 
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. 
  • Sequencing and characterization of oligosaccharides using infrared multiphoton dissociation and boronic acid derivatization in a quadrupole ion trap. 
  • Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206. 
  • Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. 
  • Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells. 
  • Tau--an inhibitor of deacetylase HDAC6 function. 
  • The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. 
  • The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. 
  • What should work, may not.